What are the side effects of dacomitinib/dacomitinib?

Dacomitinib/Dacomitinib (Dacomitinib), as a drug for the treatment of non-small cell lung cancer, has shown certain efficacy in clinical application, but it is also accompanied by a series of side effects. According to statistics from clinical studies, more than 20% of patients taking this drug experienced multiple adverse reactions.

Among them, the most common side effects include diarrhea, rash, paronychia, stomatitis, etc. Although these symptoms are not life-threatening, they can cause discomfort to patients and affect their quality of life. In addition, some patients experience symptoms such as loss of appetite, dry skin, weight loss, hair loss, cough and itching. These symptoms may be related to the stimulation of the body by the drug, or may be related to individual differences among patients.

In addition to these common adverse reactions, dacomitinib may also cause some laboratory test abnormalities. For example, patients may have blood system problems such as anemia, lymphopenia, hypoalbuminemia, etc., as well as elevated liver function indicators such as ALT and AST. These abnormal indicators require close monitoring and timely adjustment of treatment plans to ensure patient safety.

In addition, 27% of patients experienced serious adverse reactions after taking dacomitinib, the most common of which were diarrhea and interstitial lung disease. These symptoms may require special medical intervention to avoid worsening of the condition. At the same time, more than half of the patients needed to interrupt treatment due to adverse reactions, with the most common reasons being rash, paronychia, and diarrhea. A further 18% of patients had to permanently discontinue dacomitinib due to intolerable adverse reactions, such as rash, interstitial lung disease, stomatitis, and diarrhea.